Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice

Shang Xue Yan, Xiao Mei Deng, Qingtong Wang, Xiao Jing Sun, Wei Wei

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim:A number of evidence shows that the differentiation of B lymphocytes into plasma cells plays an important role in lupus pathogenesis. In this study we investigated how prednisone, a classical therapeutic drug for autoimmune diseases, regulated plasma cell differentiation in MRL/MpSlac-lpr mice.Methods:MRL/lpr mice were treated with prednisone (2.5 or 5 mg·kg -1 ·d -1, ig) for 13 weeks, and the proteinuria levels and survival times were monitored. After the mice were euthanized, blood sample, spleen and thymus were collected. The serum levels of anti-dsDNA antibody, anti-nuclear antibody, IL-21, and IL-10 were detected using ELISA kits. Subsets of splenic B and T lymphocytes were quantified with flow cytometry. Transcription factor Blimp-1 and Bcl-6 expression was determined using qPCR and Western blot.Results:Prednisone treatment dose-dependently attenuated the lupus symptoms in MRL/lpr mice with decreased proteinuria levels, prolonged survival times, decreased serum anti-nuclear antibody levels, and reduced spleen and thymus indices. Prednisone treatment also significantly decreased the elevated percentages of plasma cells and plasma cell precursors, decreased the percentages of activated T cells, and increased the frequency of CD4 + CD62L + cells, demonstrated that decreased anti-nuclear antibodies and improvements in lupus symptoms were associated with decreased plasma cells. Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice.Conclusion:Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6.

Original languageEnglish (US)
Pages (from-to)1367-1376
Number of pages10
JournalActa Pharmacologica Sinica
Volume36
Issue number11
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Inbred MRL lpr Mouse
Prednisone
Plasma Cells
B-Lymphocytes
Anti-Idiotypic Antibodies
Proteinuria
Interleukin-10
Thymus Gland
Therapeutics
Cell Differentiation
Spleen
Serum
B-Lymphocyte Subsets
T-Lymphocyte Subsets
Autoimmune Diseases
Flow Cytometry
Transcription Factors
Western Blotting
Enzyme-Linked Immunosorbent Assay
T-Lymphocytes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. / Yan, Shang Xue; Deng, Xiao Mei; Wang, Qingtong; Sun, Xiao Jing; Wei, Wei.

In: Acta Pharmacologica Sinica, Vol. 36, No. 11, 01.11.2015, p. 1367-1376.

Research output: Contribution to journalArticle

Yan, Shang Xue ; Deng, Xiao Mei ; Wang, Qingtong ; Sun, Xiao Jing ; Wei, Wei. / Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. In: Acta Pharmacologica Sinica. 2015 ; Vol. 36, No. 11. pp. 1367-1376.
@article{44864f6346534066b5aca4190b3948ea,
title = "Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice",
abstract = "Aim:A number of evidence shows that the differentiation of B lymphocytes into plasma cells plays an important role in lupus pathogenesis. In this study we investigated how prednisone, a classical therapeutic drug for autoimmune diseases, regulated plasma cell differentiation in MRL/MpSlac-lpr mice.Methods:MRL/lpr mice were treated with prednisone (2.5 or 5 mg·kg -1 ·d -1, ig) for 13 weeks, and the proteinuria levels and survival times were monitored. After the mice were euthanized, blood sample, spleen and thymus were collected. The serum levels of anti-dsDNA antibody, anti-nuclear antibody, IL-21, and IL-10 were detected using ELISA kits. Subsets of splenic B and T lymphocytes were quantified with flow cytometry. Transcription factor Blimp-1 and Bcl-6 expression was determined using qPCR and Western blot.Results:Prednisone treatment dose-dependently attenuated the lupus symptoms in MRL/lpr mice with decreased proteinuria levels, prolonged survival times, decreased serum anti-nuclear antibody levels, and reduced spleen and thymus indices. Prednisone treatment also significantly decreased the elevated percentages of plasma cells and plasma cell precursors, decreased the percentages of activated T cells, and increased the frequency of CD4 + CD62L + cells, demonstrated that decreased anti-nuclear antibodies and improvements in lupus symptoms were associated with decreased plasma cells. Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice.Conclusion:Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6.",
author = "Yan, {Shang Xue} and Deng, {Xiao Mei} and Qingtong Wang and Sun, {Xiao Jing} and Wei Wei",
year = "2015",
month = "11",
day = "1",
doi = "10.1038/aps.2015.76",
language = "English (US)",
volume = "36",
pages = "1367--1376",
journal = "Acta Pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice

AU - Yan, Shang Xue

AU - Deng, Xiao Mei

AU - Wang, Qingtong

AU - Sun, Xiao Jing

AU - Wei, Wei

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Aim:A number of evidence shows that the differentiation of B lymphocytes into plasma cells plays an important role in lupus pathogenesis. In this study we investigated how prednisone, a classical therapeutic drug for autoimmune diseases, regulated plasma cell differentiation in MRL/MpSlac-lpr mice.Methods:MRL/lpr mice were treated with prednisone (2.5 or 5 mg·kg -1 ·d -1, ig) for 13 weeks, and the proteinuria levels and survival times were monitored. After the mice were euthanized, blood sample, spleen and thymus were collected. The serum levels of anti-dsDNA antibody, anti-nuclear antibody, IL-21, and IL-10 were detected using ELISA kits. Subsets of splenic B and T lymphocytes were quantified with flow cytometry. Transcription factor Blimp-1 and Bcl-6 expression was determined using qPCR and Western blot.Results:Prednisone treatment dose-dependently attenuated the lupus symptoms in MRL/lpr mice with decreased proteinuria levels, prolonged survival times, decreased serum anti-nuclear antibody levels, and reduced spleen and thymus indices. Prednisone treatment also significantly decreased the elevated percentages of plasma cells and plasma cell precursors, decreased the percentages of activated T cells, and increased the frequency of CD4 + CD62L + cells, demonstrated that decreased anti-nuclear antibodies and improvements in lupus symptoms were associated with decreased plasma cells. Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice.Conclusion:Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6.

AB - Aim:A number of evidence shows that the differentiation of B lymphocytes into plasma cells plays an important role in lupus pathogenesis. In this study we investigated how prednisone, a classical therapeutic drug for autoimmune diseases, regulated plasma cell differentiation in MRL/MpSlac-lpr mice.Methods:MRL/lpr mice were treated with prednisone (2.5 or 5 mg·kg -1 ·d -1, ig) for 13 weeks, and the proteinuria levels and survival times were monitored. After the mice were euthanized, blood sample, spleen and thymus were collected. The serum levels of anti-dsDNA antibody, anti-nuclear antibody, IL-21, and IL-10 were detected using ELISA kits. Subsets of splenic B and T lymphocytes were quantified with flow cytometry. Transcription factor Blimp-1 and Bcl-6 expression was determined using qPCR and Western blot.Results:Prednisone treatment dose-dependently attenuated the lupus symptoms in MRL/lpr mice with decreased proteinuria levels, prolonged survival times, decreased serum anti-nuclear antibody levels, and reduced spleen and thymus indices. Prednisone treatment also significantly decreased the elevated percentages of plasma cells and plasma cell precursors, decreased the percentages of activated T cells, and increased the frequency of CD4 + CD62L + cells, demonstrated that decreased anti-nuclear antibodies and improvements in lupus symptoms were associated with decreased plasma cells. Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice.Conclusion:Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6.

UR - http://www.scopus.com/inward/record.url?scp=84946543322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946543322&partnerID=8YFLogxK

U2 - 10.1038/aps.2015.76

DO - 10.1038/aps.2015.76

M3 - Article

C2 - 26456588

AN - SCOPUS:84946543322

VL - 36

SP - 1367

EP - 1376

JO - Acta Pharmacologica Sinica

JF - Acta Pharmacologica Sinica

SN - 1671-4083

IS - 11

ER -